$2.25 billion: What Moderna Bought Isn't Just the COVID-19 Vaccine

The $2.25 billion that Moderna (hereinafter referred to as Moderna) paid out seems to be for a COVID-19 vaccine. In fact, what it bought is the qualification for the entire mRNA (messenger ribonucleic acid) infectious disease product line to continue moving forward. On the surface, this global settlement is about vaccine patents, but what's truly valuable is LNP (lipid nanoparticles) - the underlying messenger platform that encapsulates mRNA and safely delivers it into cells. mRNA is the instruction, and LNP is the shell; COVID-19 is just the battlefield, and the platform is the target.

A week ago, Moderna reached a global settlement with Arbutus and Genevant regarding the LNP patent dispute. On the surface, this is a large settlement payment; looking deeper, it's more like a platform pass.

Moderna first paid $950 million, and another $1.3 billion is linked to the result of subsequent appeals. More importantly, it obtained a paid, royalty-free, irrevocable, and non-exclusive global license. This arrangement not only applies to Spikevax but also covers mRESVIA, mNEXSPIKE, and some future infectious disease vaccine pipelines.

This means that what Moderna bought is not just the past of the COVID-19 vaccine but also the certainty for the future product line to continue advancing.

For a platform-based biotech company, what's truly terrifying is never just how much money to pay, but rather that for every new product it develops in the future, it has to carry the risks of lawsuits, injunctions, and continuous royalties. The reason the settlement is expensive is not because the lawsuit itself is worth that much, but because the future without a settlement could be even more costly.

What's most worth noting in this lawsuit is not the words "COVID-19 vaccine patent dispute," but that it brings a real industry situation to the forefront. The competition in mRNA is not only about "what to write" but also about "how to deliver it."

mRNA itself is just an instruction, and LNP is the transportation system that safely delivers this instruction into cells and truly turns it into a product. Without this delivery shell, it's difficult for mRNA to move from the laboratory to the clinic, let alone to commercialization.

So, on the surface, this lawsuit is about vaccines, but in essence, it's about the platform. On the surface, it's about infringement liability, but in essence, it's about who has the right to continue collecting money from the platform.

In the past few years, when the industry talked about mRNA, it was more easily attracted by antigen design, clinical speed, and sales curves. But Moderna's settlement has nailed down another colder and harder fact. What can generate long-term revenue is not just the finally launched products but also the underlying technology system that supports these products.

COVID-19 has pushed mRNA to the center of the stage, and LNP determines who can stand on this stage and collect fees in the long term.

At this stage, the impact of this settlement on Chinese companies and the Chinese market is more structural and indirect rather than an immediate direct risk to a particular company.

But the signal it sends is very clear.

First, when developing nucleic acid drugs, mRNA vaccines, siRNA, or even more general delivery platforms, what truly can't be bypassed is not just sequences, targets, and indications but also the free implementation space at the delivery layer. If you want to go global, engage in cross-border BD, and enter the mainstream markets in Europe and the United States, "messenger patents" can no longer be regarded as a legal issue to be addressed in the later stages of clinical trials. It has become a pre - R & D issue.

Second, Chinese companies are not without opportunities. The key lies in route selection. If they continue to follow the traditional paths that are already highly crowded globally and densely patented, the licensing costs, circumvention designs, and patent clearances will become increasingly expensive when entering the international market in the future. However, if they can make early arrangements in new delivery systems, ionizable lipids, independent process routes, or even alternative platforms, Chinese companies may not necessarily be the ones who can only pay passively.

Third, in the next round, what's truly valuable may not just be "I can also develop mRNA," but three more substantial things: Do I have my own LNP? Can I bypass others' LNP? Can I license my own messenger platform to others?

These three things determine not just the profit of a single product but a company's position in the next - round platform competition.

Intellectual Property Power's Judgment

Moderna's $2.25 billion seems to be settling the bill for the COVID-19 vaccine era, but in essence, it's buying a way for the mRNA platform era.

What it bought is not just the end of the lawsuit but also the qualification for the future product line to continue moving forward.

This settlement also shows once again that in today's biopharmaceutical industry, what's becoming more and more valuable is not a single blockbuster product but the underlying platform behind the products; what's becoming more and more dangerous is not "whether there is sales volume" but "whether there is the right to continue selling, producing, and expanding." COVID-19 is just the most prominent battlefield, and LNP is the real ticket to this war. What Moderna paid is not a vaccine settlement but a toll for the mRNA era.

This article is from the WeChat official account "Intellectual Property Power" (ID: zhichanli), author: Shawn, published by 36Kr with authorization.